Cyclosporine, tacrolimus, and mycophenolate mofetil in the treatment of inflammatory bowel disease

Gastroenterology Clinics of North America

Volumn 33, Issue 2, 2004, Pages 141-169

  Loftus, Conor G ^a,b   Egan, Laurence J ^a,b   Sandborn, William J ^a,b  

^a MAYO CLINIC   (United States)

^b MAYO CLINIC COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TOCOPHEROL; AZATHIOPRINE; CALCINEURIN INHIBITOR; CORTICOSTEROID; CYCLOSPORIN; CYCLOSPORIN A; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; MERCAPTOPURINE; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; PREDNISONE; RAPAMYCIN; TACROLIMUS; URSODEOXYCHOLIC ACID;

ANAPHYLAXIS; ASPERGILLOSIS; BACTERIAL MENINGITIS; BONE MARROW SUPPRESSION; CEREBRAL BLINDNESS; CHOLESTASIS; CLINICAL TRIAL; COLITIS; COLON CANCER; CONJUNCTIVITIS; CORRELATION ANALYSIS; CROHN DISEASE; CYTOMEGALOVIRUS INFECTION; DEPRESSION; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; ENTERITIS; ESOPHAGITIS; EXTERNAL OPHTHALMOPLEGIA; GASTROINTESTINAL HEMORRHAGE; GINGIVA HYPERPLASIA; GRAND MAL SEIZURE; HEADACHE; HERPES ZOSTER; HUMAN; HYPERTENSION; HYPERTRICHOSIS; INFECTION; INSOMNIA; KIDNEY DISEASE; KIDNEY FAILURE; LEG CRAMP; LIVER TOXICITY; LUNG ABSCESS; LUNG EMBOLISM; LYMPHOMA; LYMPHOPROLIFERATIVE DISEASE; MIGRAINE; MYCOTIC ANEURYSM; NAUSEA; NEPHROTOXICITY; OPPORTUNISTIC INFECTION; OPTIC NERVE DISEASE; PARESTHESIA; PAROTITIS; PNEUMONIA; PRURITUS; RASH; REMISSION; REVIEW; SEIZURE; SEPSIS; TREATMENT OUTCOME; TREMOR; ULCERATIVE COLITIS; UPPER RESPIRATORY TRACT INFECTION; VOMITING;

CYCLOSPORINE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFLAMMATORY BOWEL DISEASES; MYCOPHENOLIC ACID; TACROLIMUS;

EID: 2942562539     PISSN: 08898553     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.gtc.2004.02.001     Document Type: Review

References (154)

1. Podolsky D.K. Inflammatory bowel disease. [comment] N Engl J Med. 347:2002;417-429
2. Hess A.D., Tutschka P.J., Santos G.W. Effect of cyclosporin A on human lymphocyte responses in vitro III. CsA inhibits the production of T lymphocyte growth factors in secondary mixed lymphocyte responses but does not inhibit the response of primed lymphocytes to TCGF. J Immunol. 128:1982;355-359
3. Liu J., Farmer J.D. Jr., Lane W.S., Friedman J., Weissman I., Schreiber S.L. Calcineurin is a common target of cyclophilin-cyclosporin A and FKBP-FK506 complexes. Cell. 66:1991;807-815
4. Reed J.C., Prystowsky M.B., Nowell P.C. Regulation of gene expression in lectin-stimulated or lymphokine-stimulated T lymphocytes: effects of cyclosporine. Transplantation. 46:1988;85S-89S
5. Kahan B.D. Cyclosporine. [comment] N Engl J Med. 321:1989;1725-1738
6. Ptachcinski R.J., Venkataramanan R., Burckart G.J. Clinical pharmacokinetics of cyclosporin. Clin Pharmacokinet. 11:1986;107-132
7. Min D.I., Hwang G.C., Bergstrom S., et al. Bioavailability and patient acceptance of cyclosporine soft gelatin capsules in renal allograft recipients. Ann Pharmacother. 26:1992;175-179
8. Drewe J., Beglinger C., Kissel T. The absorption site of cyclosporin in the human gastrointestinal tract. Br J Clin Pharmacol. 33:1992;39-43
9. Brynskov J., Freund L., Campanini M.C., Kampmann J.P. Cyclosporin pharmacokinetics after intravenous and oral administration in patients with Crohn's disease. Scand J Gastroenterol. 27:1992;961-967
10. Roberts R., Sketris I.S., Abraham I., Givner M.L., MacDonald A.S. Cyclosporine absorption in two patients with short-bowel syndrome. Drug Intell Clin Pharm. 22:1988;570-572
11. Venkataramanan R., Burckhart G.J., Ptachcinski R.J. Pharmacokinetics and monitoring of cyclosporine following orthotopic liver transplantation. Semin Liver Dis. 5:1985;357-368
12. Sokol R.J., Johnson K.E., Karrer F.M., Narkewicz M.R., Smith D., Kam I. Improvement of cyclosporin absorption in children after liver transplantation by means of water-soluble vitamin E. [comment] Lancet. 338:1991;212-214
13. Gutzler F., Zimmermann R., Ring G.H., Sauer P., Stiehl A. Ursodeoxycholic acid enhances the absorption of cyclosporine in a heart transplant patient with short bowel syndrome. Transplant Proc. 24:1992;2620-2621
14. Feutren G., Mihatsch M.J. Risk factors for cyclosporine-induced nephropathy in patients with autoimmune diseases. International Kidney Biopsy Registry of Cyclosporine in Autoimmune Diseases. [comment] N Engl J Med. 326:1992;1654-1660
15. Jewell D.P., Lennard-Jones J.E. Oral cyclosporin for chronic active Crohn's disease: a multicentre controlled trial. Eur J Gastroenterol Hepatol. 6:1994;499-505
16. Feagan B.G., McDonald J.W., Rochon J., et al. Low-dose cyclosporine for the treatment of Crohn's disease. The Canadian Crohn's Relapse Prevention Trial Investigators. [comment] N Engl J Med. 330:1994;1846-1851
17. Stange E.F., Modigliani R., Pena A.S., Wood A.J., Feutren G., Smith P.R. European trial of cyclosporine in chronic active Crohn's disease: a 12-month study. The European Study Group. [comment] Gastroenterology. 109:1995;774-782
18. Brynskov J., Freund L., Rasmussen S.N., et al. A placebo-controlled, double-blind, randomized trial of cyclosporine therapy in active chronic Crohn's disease. [comment] N Engl J Med. 321:1989;845-850
19. Brynskov J., Freund L., Norby Rasmussen S., et al. Final report on a placebo-controlled, double-blind, randomized, multicentre trial of cyclosporin treatment in active chronic Crohn's disease. Scand J Gastroenterol. 26:1991;689-695
20. Allison M.C., Pounder R.E. Cyclosporin for Crohn's disease. Aliment Pharmacol Ther. 1:1987;39-43
21. Peltekian K.M., Williams C.N., MacDonald A.S., Roy P.D., Czolpinska E. Open trial of cyclosporine in patients with severe active Crohn's disease refractory to conventional therapy. Can J Gastroenterol. 2:1988;5-11
22. Parrott N.R., Taylor R.M., Venables C.W., Record C.O. Treatment of Crohn's disease in relapse with cyclosporin A. Br J Surg. 75:1988;1185-1188
23. Fukushima T., Sugita A., Masuzawa S., Yamazaki Y., Tsuchiya S. Effects of cyclosporin A on active Crohn's disease. Gastroenterol Jpn. 24:1989;12-15
24. Brynskov J., Binder V., Riis P., et al. Low-dose cyclosporin for Crohn's disease: implications for clinical trials. [comment] Aliment Pharmacol Ther. 3:1989;135-142
25. Stange E.F., Fleig W.E., Rehklau E., Ditschuneit H. Cyclosporin A treatment in inflammatory bowel disease. Dig Dis Sci. 34:1989;1387-1392
26. Baker K., Jewell D.P. Cyclosporin for the treatment of severe inflammatory bowel disease. [erratum appears in Aliment Pharmacol Ther 1989;3:414] Aliment Pharmacol Ther. 3:1989;143-149
27. Lofberg R., Angelin B., Einarsson K., Gabrielsson N., Ost L. Unsatisfactory effect of cyclosporin A treatment in Crohn's disease: a report of five cases. J Intern Med. 226:1989;157-161
28. Ranzi T., Campanini M.C., Quarto Di Palo F., Velio P., Bianchi P.A. Cyclosporin A in Crohn's disease. Curr Ther Res. 45:1989;245-252
29. Ardizzone S., Fasoli R., Sangaletti O., Petrillo M., Bianchi-Porro G. The treatment of chronically active Crohn's disease with cyclosporin A. Curr Ther Res. 48:1990;1-4
30. Lichtiger S. Cyclosporine therapy in inflammatory bowel disease: open-label experience. Mt Sinai J Med. 57:1990;315-319
31. Lobo A.J., Juby L.D., Rothwell J., Poole T.W., Axon A.T. Long-term treatment of Crohn's disease with cyclosporine: the effect of a very low dose on maintenance of remission. J Clin Gastroenterol. 13:1991;42-45
32. Actis G.C., Ottobrelli A., Pera A., et al. Continuously infused cyclosporine at low dose is sufficient to avoid emergency colectomy in acute attacks of ulcerative colitis without the need for high-dose steroids. J Clin Gastroenterol. 17:1993;10-13
33. Hanauer S.B., Smith M.B. Rapid closure of Crohn's disease fistulas with continuous intravenous cyclosporin A. [comment] Am J Gastroenterol. 88:1993;646-649
34. Markowitz J. Cyclosporine lacks therapeutic efficacy in highly destructive perianal Crohn's disease associated with Crohn's disease (CD). Am J Gastroenterol. 88:1993;1620
35. Ramakrishna J., Langhans N., Calenda K., Grand R.J., Verhave M. Combined use of cyclosporine and azathioprine or 6-mercaptopurine in pediatric inflammatory bowel disease. J Pediatr Gastroenterol Nutr. 22:1996;296-302
36. Present D.H., Lichtiger S. Efficacy of cyclosporine in treatment of fistula of Crohn's disease. Dig Dis Sci. 39:1994;374-380
37. Santos J.V., Baudet J.A., Casellas F.J., Guarner L.A., Vilaseca J.M., Malagelada J.R. Intravenous cyclosporine for steroid-refractory attacks of Crohn's disease: short- and long-term results. J Clin Gastroenterol. 20:1995;207-210
38. Mahdi G., Israel D.M., Hassall E. Cyclosporine and 6-mercaptopurine for active, refractory Crohn's colitis in children. Am J Gastroenterol. 91:1996;1355-1359
39. Egan L.J., Sandborn W.J., Tremaine W.J. Clinical outcome following treatment of refractory inflammatory and fistulizing Crohn's disease with intravenous cyclosporine. Am J Gastroenterol. 93:1998;442-448
40. Taylor A.C., Connell W.R., Elliott R., d'Apice A.J. Oral cyclosporin in refractory inflammatory bowel disease. Aust N Z J Med. 28:1998;179-183
41. Hermida-Rodriguez C., Cantero Perona J., Garcia-Valriberas R., Pajares Garcia J.M., Mate-Jimenez J. High-dose intravenous cyclosporine in steroid refractory attacks of inflammatory bowel disease. Hepatogastroenterology. 46:1999;2265-2268
42. Lavy A. Long-term cyclosporine for resistant Crohn's disease. J Clin Gastroenterol. 28:1999;254-255
43. Gurudu S.R., Griffel L.H., Gialanella R.J., Das K.M. Cyclosporine therapy in inflammatory bowel disease: short-term and long-term results. [comment] J Clin Gastroenterol. 29:1999;151-154
44. Haslam N., Hearing S.D., Probert C.S. Audit of cyclosporin use in inflammatory bowel disease: limited benefits, numerous side-effects. Eur J Gastroenterol Hepatol. 12:2000;657-660
45. Barabino A., Torrente F., Castellano E., et al. The use of ciclosporin in paediatric inflammatory bowel disease: an Italian experience. Aliment Pharmacol Ther. 16:2002;1503-1507
46. Lichtiger S., Present D.H., Kornbluth A., et al. Cyclosporine in severe ulcerative colitis refractory to steroid therapy. [comment] N Engl J Med. 330:1994;1841-1845
47. D'Haens G., Lemmens L., Geboes K., et al. Intravenous cyclosporine versus intravenous corticosteroids as single therapy for severe attacks of ulcerative colitis. [comment] Gastroenterology. 120:2001;1323-1329
48. Svanoni F., Bonassi U., Bagnolo F., Caporuscio S. Effectiveness of cyclosporine A (CsA) in the treatment of active refractory ulcerative colitis (UC). [abstract] Gastroenterology. 114:1998;A1096
49. Van Assche G., D' Haens G., Noman M. Randomized double blind comparison of 4 mg/kg versus 2 mg/kg IV cyclosporine in severe ulcerative colitis. [abstract] Gastroenterology. 122:2002;A668
50. Gupta S., Keshavarzian A., Hodgson H.J. Cyclosporin in ulcerative colitis. Lancet. 2:1984;1277-1278
51. Bianchi Porro G., Panza E., Petrillo M. Cyclosporin A in acute ulcerative colitis. Ital J Gastroenterol. 19:1987;40-41
52. Shelly E.D., Shelly W.B. Cyclosporine therapy for pyoderma gangrenosum associated with sclerosing cholangitis and ulcerative colitis. J Am Acad Dermatol. 18:1988;1084-1088
53. Hyams J.S., Treem W.R. Cyclosporine treatment of fulminant colitis. J Pediatr Gastroenterol Nutr. 9:1989;383-387
54. Lichtiger S., Present D.H. Preliminary report: cyclosporin in treatment of severe active ulcerative colitis. [comment] Lancet. 336:1990;16-19
55. Bianchi Porro G., Petrillo M., Ardizzone S. Cyclosporin treatment for severe active ulcerative colitis. [comment] Lancet. 336:1990;439
56. Treem W.R., Davis P.M., Hyams J.S. Cyclosporine treatment of severe ulcerative colitis in children. J Pediatr. 119:1991;994-997
57. Sandborn W.J., Goldman D.H., Lawson G.M., Perrault J. Measurement of colonic tissue cyclosporine concentration in children with severe ulcerative colitis. J Pediatr Gastroenterol Nutr. 15:1992;125-129
58. Treem W.R., Veligati L.N., Rotter J.I., Targan S.R., Hyams J.S. Ulcerative colitis and total alopecia in a mother and her son. Gastroenterology. 104:1993;1187-1191
59. Allgayer H., Seitz K.H., Gugler R. Can cyclosporin prevent proctocolectomy in severe steroid-refractory ulcerative colitis? Lessons from a case report. Dig Dis Sci. 38:1993;380-382
60. Benkov K.J., Rosh J.R., Schwersenz A.H., Janowitz H.D., LeLeiko N.S. Cyclosporine as an alternative to surgery in children with inflammatory bowel disease. J Pediatr Gastroenterol Nutr. 19:1994;290-294
61. Kozarek R., Bedard C., Patterson D., et al. Cyclosporin use in the precolectomy chronic ulcerative colitis patient: a community experience and its relationship to prospective and controlled clinical trials. Pacific Northwest Gastroenterology Society. [comment] Am J Gastroenterol. 90:1995;2093-2096
62. Santos J., Baudet S., Casellas F., Guarner L., Vilaseca J., Malagelada J.R. Efficacy of intravenous cyclosporine for steroid refractory attacks of ulcerative colitis. J Clin Gastroenterol. 20:1995;285-289
63. Treem W.R., Cohen J., Davis P.M., Justinich C.J., Hyams J.S. Cyclosporine for the treatment of fulminant ulcerative colitis in children: immediate response, long-term results, and impact on surgery. Dis Colon Rectum. 38:1995;474-479
64. Bertschinger P., Himmelmann A., Risti B., Follath F. Cyclosporine treatment of severe ulcerative colitis during pregnancy. [comment] Am J Gastroenterol. 90:1995;330
65. Carbonnel F., Boruchowicz A., Duclos B., et al. Intravenous cyclosporine in attacks of ulcerative colitis: short-term and long-term responses. Dig Dis Sci. 41:1996;2471-2476
66. Fernandez-Banares F., Bertran X., Esteve-Comas M., et al. Azathioprine is useful in maintaining long-term remission induced by intravenous cyclosporine in steroid-refractory severe ulcerative colitis. Am J Gastroenterol. 91:1996;2498-2499
67. Van Gossum A., Schmit A., Adler M., et al. Short- and long-term efficacy of cyclosporin administration in patients with acute severe ulcerative colitis. Belgian IBD Group. Acta Gastroenterol Belg. 60:1997;197-200
68. Scott A.M., Myers G.A., Harms B.A. Pneumocystis carinii pneumonia postrestorative proctocolectomy for ulcerative colitis: a role for perioperative prophylaxis in the cyclosporine era? Report of a case and review of the literature. Dis Colon Rectum. 40:1997;973-976
69. Quan V.A., Saunders B.P., Hicks B.H., Sladen G.E. Cyclosporin treatment for ulcerative colitis complicated by fatal Pneumocystis carinii pneumonia. BMJ. 314:1997;363-364
70. Stack W.A., Long R.G., Hawkey C.J. Short- and long-term outcome of patients treated with cyclosporin for severe acute ulcerative colitis. Aliment Pharmacol Ther. 12:1998;973-978
71. Kashimura H., Hassan M., Shibahara K., et al. Steroid-refractory severe ulcerative colitis responding to cyclosporine and long-term follow-up. [comment] J Gastroenterol. 33:1998;566-570
72. van Bodegraven A.A., Linskens R.K., van Haelst I.M., Sindram J.W., Tuynman H.A. Addition of low-dose oral cyclosporine in severe ulcerative colitis-pharmacokinetics and clinical outcome report of twelve cases. J Clin Gastroenterol. 27:1998;72-73
73. Hyde G.M., Thillainayagam A.V., Jewell D.P. Intravenous cyclosporin as rescue therapy in severe ulcerative colitis: time for a reappraisal? Eur J Gastroenterol Hepatol. 10:1998;411-413
74. Wenzl H.H., Petritsch W., Aichbichler B.W., Hinterleitner T.A., Fleischmann G., Krejs G.J. Short-term efficacy and long-term outcome of cyclosporine treatment in patients with severe ulcerative colitis. Z Gastroenterol. 36:1998;287-293
75. Cohen R.D., Stein R., Hanauer S.B. Intravenous cyclosporin in ulcerative colitis: a five-year experience. [comment] Am J Gastroenterol. 94:1999;1587-1592
76. Naftali T., Novis B., Pomeranz I., et al. Cyclosporin for severe ulcerative colitis. [comment] Isr Med Assoc J. 2:2000;588-591
77. Rowe F.A., Walker J.H., Karp L.C., Vasiliauskas E.A., Plevy S.E., Targan S.R. Factors predictive of response to cyclosporin treatment for severe, steroid-resistant ulcerative colitis. Am J Gastroenterol. 95:2000;2000-2008
78. Hinterreiter M., Stadler B., Knoflach P. Recurrent septicemia with lethal outcome during and after cyclosporine therapy in severe ulcerative colitis. Acta Med Austriaca. 27:2000;91-93
79. Pinna-Pintor M., Arese P., Bona R., et al. Severe steroid-unresponsive ulcerative colitis: outcomes of restorative proctocolectomy in patients undergoing cyclosporin treatment. Dis Colon Rectum. 43:2000;609-613. [discussion 613-4]
80. Rolny P., Sadik R. Longer term outcome of steroid refractory ulcerative colitis treated with intravenous cyclosporine without subsequent oral cyclosporine maintenance therapy. Int J Colorectal Dis. 17:2002;67-69
81. McCormack G., McCormick P.A., Hyland J.M., O'Donoghue D.P. Cyclosporin therapy in severe ulcerative colitis: is it worth the effort? Dis Colon Rectum. 45:2002;1200-1205
82. Chiba T., Orii S., Shitomi T., et al. Effects of cyclosporine in steroid-refractory severe acute ulcerative colitis. J Clin Gastroenterol. 34:2002;101-102
83. Actis G.C., Aimo G., Priolo G., Moscato D., Rizzetto M., Pagni R. Efficacy and efficiency of oral microemulsion cyclosporin versus intravenous and soft gelatin capsule cyclosporin in the treatment of severe steroid-refractory ulcerative colitis: an open-label retrospective trial. Inflamm Bowel Dis. 4:1998;276-279
84. Actis G.C., Bresso F., Astegiano M., et al. Safety and efficacy of azathioprine in the maintenance of cyclosporin-induced remission of ulcerative colitis. Aliment Pharmacol Ther. 15:2001;1307-1311
85. Wenzl H., Petritsch W., Reicht G., Eherer A., Krejs G.J. Cyclosporin for the treatment of severe ulcerative colitis. Z Gastroenterol. 32:1994;137-140
86. Sandborn W.J., Tremaine W.J., Schroeder K.W., et al. A placebo-controlled trial of cyclosporine enemas for mildly to moderately active left-sided ulcerative colitis. Gastroenterology. 106:1994;1429-1435
87. Brynskov J., Freund L., Thomsen O.O., Andersen C.B., Rasmussen S.N., Binder V. Treatment of refractory ulcerative colitis with cyclosporin enemas. [comment] Lancet. 1:1989;721-722
88. Ranzi T., Campanini M.C., Velio P., Quarto di Palo F., Bianchi P. Treatment of chronic proctosigmoiditis with cyclosporin enemas. [comment] Lancet. 2:1989;97
89. Sandborn W.J., Tremaine W.J., Schroeder K.W., Steiner B.L., Batts K.P., Lawson G.M. Cyclosporine enemas for treatment-resistant, mildly to moderately active, left-sided ulcerative colitis. [comment] Am J Gastroenterol. 88:1993;640-645
90. Winter T.A., Dalton H.R., Merrett M.N., Campbell A., Jewell D.P. Cyclosporin A retention enemas in refractory distal ulcerative colitis and 'pouchitis'. Scand J Gastroenterol. 28:1993;701-704
91. Sanghvi A., Diven W.F., Warty V.S., Starzl T. Cyclosporine measurement by fluorescent polarization immunoassay utilizing Abbott TDx instrument. Transplant Proc. 21:1989;898-900
92. Sandborn W.J. A critical review of cyclosporine therapy in inflammatory bowel disease. Inflamm Bowel Dis. 1:1995;48-63
93. Palestine A.G., Nussenblatt R.B., Chan C.C. Side effects of systemic cyclosporine in patients not undergoing transplantation. Am J Med. 77:1984;652-656
94. Tegzess A.M., Doorenbos B.M., Minderhoud J.M., Donker A.J. Prospective serial renal function studies in patients with nonrenal disease treated with cyclosporine A. Transplant Proc. 20:1988;390-393
95. Ross E.A., Wilkinson A., Hawkins R.A., Danovitch G.M. The plasma creatinine concentration is not an accurate reflection of the glomerular filtration rate in stable renal transplant patients receiving cyclosporine. Am J Kidney Dis. 10:1987;113-117
96. Smith M.B., Hanauer S.B. Pneumocystis carinii pneumonia during cyclosporine therapy for ulcerative colitis. N Engl J Med. 327:1992;497-498
97. Scalzini A., Barni C., Stellini R., Sueri L. Fatal invasive aspergillosis during cyclosporine and steroids treatment for Crohn's disease. Dig Dis Sci. 40:1995;528
98. D'Haens G., Suenaert P., Westhovens R., Rutgeerts P. Severe knee pain as the single symptom of CMV infection in acute ulcerative colitis treated with cyclosporine. Inflamm Bowel Dis. 4:1998;27-28
99. Vega R., Bertran X., Menacho M., et al. Cytomegalovirus infection in patients with inflammatory bowel disease. Am J Gastroenterol. 94:1999;1053-1056
100. Caroli A., Fregonese D., Di Falco G., D'Inca R. Aspergillus fumigatus pneumonia during cyclosporine treatment for ulcerative colitis. Am J Gastroenterol. 95:2000;3016-3017
101. Stack W.A., Richardson P.D., Logan R.P., Mahida Y.R., Hawkey C.J. Nocardia asteroides lung abscess in acute ulcerative colitis treated with cyclosporine. Am J Gastroenterol. 96:2001;2255-2256
102. Lorber M.I., Van Buren C.T., Flechner S.M., Williams C., Kahan B.D. Hepatobiliary complications of cyclosporine therapy following renal transplantation. Transplant Proc. 19:1987;1808-1810
103. Stacey N.H., Kotecka B. Inhibition of taurocholate and ouabain transport in isolated rat hepatocytes by cyclosporin A. Gastroenterology. 95:1988;780-786
104. Actis G.C., Debernardi-Venon W., Lagget M., et al. Hepatotoxicity of intravenous cyclosporin A in patients with acute ulcerative colitis on total parenteral nutrition. Liver. 15:1995;320-323
105. Moore R.A., Greenberg E., Tangen L. Cyclosporine-induced worsening of hepatic dysfunction in a patient with Crohn's disease and enterocutaneous fistula. South Med J. 88:1995;843-844
106. Chicharro M., Guarner L., Vilaseca J., Planas M., Malagelada J. Does cyclosporin A worsen liver function in patients with inflammatory bowel disease and total parenteral nutrition? Rev Esp Enferm Dig. 92:2000;68-77
107. Barabino A., Castellano E., Gandullia P., Biscaldi E. A girl with severe fistulizing Crohn's disease. Dig Liver Dis. 32:2000;792-794
108. Rosencrantz R., Moon A., Raynes H., Spivak W. Cyclosporine-induced neurotoxicity during treatment of Crohn's disease: lack of correlation with previously reported risk factors. Am J Gastroenterol. 96:2001;2778-2782
109. de Groen P.C., Aksamit A.J., Rakela J., Forbes G.S., Krom R.A. Central nervous system toxicity after liver transplantation: the role of cyclosporine and cholesterol. N Engl J Med. 317:1987;861-866
110. Sandborn W.J. A review of immune modifier therapy for inflammatory bowel disease: azathioprine, 6-mercaptopurine, cyclosporine, and methotrexate. [comment] Am J Gastroenterol. 91:1996;423-433
111. Porges Y., Blumen S., Fireman Z., Sternberg A., Zamir D. Cyclosporine-induced optic neuropathy, ophthalmoplegia, and nystagmus in a patient with Crohn disease. Am J Ophthalmol. 126:1998;607-609
112. Cockburn I.T., Krupp P. The risk of neoplasms in patients treated with cyclosporine A. J Autoimmun. 2:1989;723-731
113. Feutren G., von Graffenried B. Pharmacology of cyclosporin A (Sandimmun) and clinical experience in inflammatory bowel diseases. Schweizerische Medizinische Wochenschrift. Journal Suisse de Medecine. 121:1991;748-753
114. Kornbluth A., Present D.H., Lichtiger S., Hanauer S. Cyclosporin for severe ulcerative colitis: a user's guide. [comment] Am J Gastroenterol. 92:1997;1424-1428
115. Drewe J., Meier R., Vonderscher J., et al. Enhancement of the oral absorption of cyclosporin in man. Br J Clin Pharmacol. 34:1992;60-64
116. Mueller E.A., Kovarik J.M., van Bree J.B., Tetzloff W., Grevel J., Kutz K. Improved dose linearity of cyclosporine pharmacokinetics from a microemulsion formulation. Pharm Res. 11:1994;301-304
117. Kovarik J.M., Mueller E.A., van Bree J.B., et al. Reduced inter- and intraindividual variability in cyclosporine pharmacokinetics from a microemulsion formulation: bioequivalence of soft gelatin capsules and oral solution of a new cyclosporine formulation. J Pharm Sci. 83:1994;444-446
118. Ferrea G., Fioredda F., Loy A., Mangraviti S., Rossi G., Bassetti D. Oral microemulsion formulation substitutes for intravenous cyclosporin in child with graft-versus-host disease. Lancet. 344:1994;480-481
119. Trull A.K., Tan K.K., Uttridge J., Bauer T., Alexander G.J., Jamieson N.V. Cyclosporin absorption from microemulsion formulation in liver transplant recipient. Lancet. 341:1993;433
120. Kovarik J.M., Mueller E.A., Johnston A., Hitzenberger G., Kutz K. Bioequivalence of soft gelatin capsules and oral solution of a new cyclosporine formulation. Pharmacotherapy. 13:1993;613-617
121. Frei U.A., Neumayer H.H., Buchholz B., Niese D., Mueller E.A. Randomized, double-blind, one-year study of the safety and tolerability of cyclosporine microemulsion compared with conventional cyclosporine in renal transplant patients. International Sandimmun Neoral Study Group. Transplantation. 65:1998;1455-1460
122. Actis G.C., Volpes R., Rizzetto M. Oral microemulsion cyclosporin to reduce steroids rapidly in chronic active ulcerative colitis. Eur J Gastroenterol Hepatol. 11:1999;905-908
123. Navazo L., Salata H., Morales S., et al. Oral microemulsion cyclosporine in the treatment of steroid-refractory attacks of ulcerative and indeterminate colitis. Scand J Gastroenterol. 36:2001;610-614
124. Flanagan W.M., Corthesy B., Bram R.J., Crabtree G.R. Nuclear association of a T-cell transcription factor blocked by FK-506 and cyclosporin A. [comment] Nature. 352:1991;803-807
125. Peters D.H., Fitton A., Plosker G.L., Faulds D. Tacrolimus: a review of its pharmacology, and therapeutic potential in hepatic and renal transplantation. Drugs. 46:1993;746-794
126. Spencer C.M., Goa K.L., Gillis J.C. Tacrolimus: an update of its pharmacology and clinical efficacy in the management of organ transplantation. Drugs. 54:1997;925-975
127. Plosker G.L., Foster R.H. Tacrolimus: a further update of its pharmacology and therapeutic use in the management of organ transplantation. Drugs. 59:2000;323-389
128. Jain A.B., Venkataramanan R., Cadoff E., et al. Effect of hepatic dysfunction and T tube clamping on FK 506 pharmacokinetics and trough concentrations. Transplant Proc. 22:1990;57-59
129. Jain A., Venkataramanan R., Lever J., et al. FK 506 in small bowel transplant recipients: pharmacokinetics and dosing. Transplant Proc. 26:1994;1609-1610
130. Bousvaros A., Leichtner A.M., Book L., et al. Treatment of pediatric autoimmune enteropathy with tacrolimus (FK506). Gastroenterology. 111:1996;237-243
131. Sandborn W.J., Present D.H., Isaacs K.L., et al. Tacrolimus for the treatment of fistulas in patients with Crohn's disease: a randomized, placebo-controlled trial. Gastroenterology. 125:2003;380-388
132. Sandborn W.J. Preliminary report on the use of oral tacrolimus (FK506) in the treatment of complicated proximal small bowel and fistulizing Crohn's disease. Am J Gastroenterol. 92:1997;876-879
133. Lowry P.W., Weaver A.L., Tremaine W.J., Sandborn W.J. Combination therapy with oral tacrolimus (FK506) and azathioprine or 6-mercaptopurine for treatment-refractory Crohn's disease perianal fistulae. Inflamm Bowel Dis. 5:1999;239-245
134. Bousvaros A., Kirschner B.S., Werlin S.L., et al. Oral tacrolimus treatment of severe colitis in children. J Pediatr. 137:2000;794-799
135. Ierardi E., Principi M., Francavilla R., et al. Oral tacrolimus long-term therapy in patients with Crohn's disease and steroid resistance. Aliment Pharmacol Ther. 15:2001;371-377
136. Fellermann K., Herrlinger K.R., Witthoeft T., Homann N., Ludwig D., Stange E.F. Tacrolimus: a new immunosuppressant for steroid refractory inflammatory bowel disease. Transplant Proc. 33:2001;2247-2248
137. Matsuhashi N., Nakajima A., Watanabe K., et al. Tacrolimus in corticosteroid-resistant ulcerative colitis. [comment] J Gastroenterol. 35:2000;635-640
138. Gremillion R.B., Posever J.O., Manek N., West J.P., van Volen-Hoven R.F. Tacrolimus (FK506) in the treatment of severe, refractory rheumatoid arthritis: initial experience in 12 patients. J Rheumatol. 26:1999;2332-2336
139. Lipsky J.J. Mycophenolate mofetil. Lancet. 348:1996;1357-1359
140. Zeeh J.M., Zorlu, Riley N.E., et al. Mycophenolate mofetil reduces tissue damage and inflammation in an experimental model of colitis in rats. Scand J Gastroenterol. 36:2001;66-70
141. Sollinger H.W. Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients. US Renal Transplant Mycophenolate Mofetil Study Group. Transplantation. 60:1995;225-232
142. Mathew T.H. A blinded, long-term, randomized multicenter study of mycophenolate mofetil in cadaveric renal transplantation: results at three years. Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group. [erratum appears in Transplantation 1998;66:817] Transplantation. 66:1998;1450-1454
143. Wiesel M., Carl S. A placebo controlled study of mycophenolate mofetil used in combination with cyclosporine and corticosteroids for the prevention of acute rejection in renal allograft recipients: 1-year results. The European Mycophenolate Mofetil Cooperative Study Group. J Urol. 159:1998;28-33
144. Neurath M.F., Wanitschke R., Peters M., Krummenauer F., Meyer zum Buschenfelde K.H., Schlaak J.F. Randomised trial of mycophenolate mofetil versus azathioprine for treatment of chronic active Crohn's disease. [comment] Gut. 44:1999;625-628
145. Orth T., Peters M., Schlaak J.F., et al. Mycophenolate mofetil versus azathioprine in patients with chronic active ulcerative colitis: a 12-month pilot study. Am J Gastroenterol. 95:2000;1201-1207
146. Fickert P., Hinterleitner T.A., Wenzl H.H., Aichbichler B.W., Petritsch W. Mycophenolate mofetil in patients with Crohn's disease. [comment] Am J Gastroenterol. 93:1998;2529-2532
147. Florin T.H., Roberts R.K., Watson M.R., Radford-Smith G.L. Treatment of steroid refractory inflammatory bowel disease (IBD) with mycophenolate mofetil (MMF). Aust N Z J Med. 28:1998;344-345
148. Fellermann K., Steffen M., Stein J., et al. Mycophenolate mofetil: lack of efficacy in chronic active inflammatory bowel disease. Aliment Pharmacol Ther. 14:2000;171-176
149. Hassard P.V., Vasiliauskas E.A., Kam L.Y., Targan S.R., Abreu M.T. Efficacy of mycophenolate mofetil in patients failing 6-mercaptopurine or azathioprine therapy for Crohn's disease. Inflamm Bowel Dis. 6:2000;16-20
150. Treiber G. Mycophenolate mofetil for therapy-resistant interstitial lung disease associated with ulcerative colitis. [comment] Am J Gastroenterol. 95:2000;3674-3675
151. Miehsler W., Reinisch W., Moser G., Gangl A., Vogelsang H. Is mycophenolate mofetil an effective alternative in azathioprine-intolerant patients with chronic active Crohn's disease? Am J Gastroenterol. 96:2001;782-787
152. Skelly M.M., Logan R.F., Jenkins D., Mahida Y.R., Hawkey C.J. Toxicity of mycophenolate mofetil in patients with inflammatory bowel disease. Inflamm Bowel Dis. 8:2002;93-97
153. Golconda M.S., Valente J.F., Bejarano P., Gilinsky N., First M.R. Mycophenolate mofetil-induced colonic ulceration in renal transplant recipients. Transplant Proc. 31:1999;272-273
154. Shaw L.M., Nowak I. Mycophenolic acid: measurement and relationship to pharmacologic effects. Ther Drug Monit. 17:1995;685-689